Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (NCT05533697)

🧪 Interventions in This Study

• mRNA-4359 (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)
• Ipilimumab (BIOLOGICAL)
• Nivolumab (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• The Angeles Clinic and Research Institute — Los Angeles, California
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• University of Colorado Cancer Center — Aurora, Colorado
• George Washington University — Washington D.C., District of Columbia
• Orlando Health UF Health Cancer Center — Orlando, Florida
• The University of Chicago Medicine — Chicago, Illinois
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Hospital — Detroit, Michigan
• Washington University — St Louis, Missouri
• John Theurer Cancer Center — Hackensack, New Jersey
• NYU Langone Health-Perlmutter Cancer Center — New York, New York
• Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics — New York, New York
• Carolina BioOncology Institute — Huntersville, North Carolina
• Oregon Health & Science University — Portland, Oregon
• Sara Cannon Research Institute Tennessee — Nashville, Tennessee
• Southside Cancer Center — Miranda, New South Wales
• Wollongong Hospital — Wollongong, New South Wales
• Melanoma Institute Australia — Wollstonecraft, New South Wales
• Austin Hospital — Melbourne, Victoria
• One Clinical Research — Nedlands, Western Australia
• Lungenfachklinik Immenhausen - Thoracic Oncology — Immenhausen, Hesse
• A.O. Santa Maria della Misericordia — Udine, Perugia
• Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie — Warsaw, Masovia
• South Texas Accelerated Research Therapeutics (START) - Rioja — Logroño, La Rioja

📞 Contact the Study Coordinator

Phone: (866) 663-3762

Email: WeCareClinicalTrials@modernatx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumors

• A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors — Scottsdale, Arizona
• A Study of MGC028 in Participants With Advanced Solid Tumors — San Francisco, California
• A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) — Tampa, Florida
• A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. — Fairfax, Virginia
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors — Los Angeles, California

Explore by condition: All Advanced Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.